11/20
03:46 pm
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.
Low
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Cantor Fitzgerald from a "neutral" rating to an "overweight" rating.
11/19
08:30 am
acrs
Rating for ACRS
High
Report
Rating for ACRS
11/19
08:29 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
High
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at Leerink Partners from a "market perform" rating to an "outperform" rating. They now have a $7.00 price target on the stock, up previously from $2.00.
11/19
08:12 am
acrs
Rating for ACRS
High
Report
Rating for ACRS
11/19
08:12 am
acrs
Rating for ACRS
High
Report
Rating for ACRS
11/19
07:30 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $8.00 price target on the stock.
High
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $8.00 price target on the stock.
11/19
04:45 am
acrs
Rating for ACRS
High
Report
Rating for ACRS
9/17
11:11 am
acrs
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) had its "neutral" rating re-affirmed by analysts at HC Wainwright.
Low
Report
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) had its "neutral" rating re-affirmed by analysts at HC Wainwright.